% | $
Quotes you view appear here for quick access.

Ligand Pharmaceuticals Incorporated Message Board

  • kennethtdc kennethtdc Apr 11, 2013 12:22 PM Flag

    From the index board

    bearofbleecker • Apr 9, 2013 11:31 AM Flag
    1users liked this postsusers disliked this posts0Reply
    Phase II Kyrpolis trial summarized in Myeloma Beacon
    This is the first brief description of the presentation made at the International Multiple Myeloma Workshop last Saturday. The subjects were high-risk "smoldering myeloma" patients. They were given the Kyrpolis/Revlimid/low-dose dexamethasone combo. All patients responded, with "75% achieving at least a near complete response". There are, as yet, no progression-free survival numbers, which would be needed to demonstrate delayed onset of MM. These results support the argument made by Anderson in the Summary Presentation, arguing for earlier intervention with combination therapies. The implication, as I noted before, is that rather than being the drug of last resort for those refractory to Velcade, Kyrpolis will be moved to the head of the line as maintenance therapy for those who previously would not have been treated at all. Less
    Sort: Newest | Oldest | Most Replied Expand all replies
    bearofbleecker • Apr 9, 2013 11:43 AM
    2users liked this postsusers disliked this posts0Reply
    As an addendum: A poster on the MM Beacon forum last Saturday relates that her husband was about to begin treatment for MM in Orlando and, having heard good things about Kyrpolis, wanted to go on the Kyrpolis/Revlimid/dex regimen, but were having trouble finding a doctor who was using it. Then, 2... More
    1 Reply to bearofbleecker
    bearofbleecker • Apr 9, 2013 3:24 PM
    1users liked this postsusers disliked this posts0Reply
    The Myeloma Beacon has now posted a more complete article detailing results of the Landgren trial in "smoldering" MM patients.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
89.85+0.91(+1.02%)Sep 4 4:00 PMEDT